RUA Life Sciences (FRA:AOHA) Debt-to-Equity : 0.12 (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Debt-to-Equity?

RUA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.15 Mil. RUA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.37 Mil. RUA Life Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €4.33 Mil. RUA Life Sciences's debt to equity for the quarter that ended in Sep. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for RUA Life Sciences's Debt-to-Equity or its related term are showing as below:

FRA:AOHA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.08 Max: 0.12
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of RUA Life Sciences was 0.12. The lowest was 0.05. And the median was 0.08.

FRA:AOHA's Debt-to-Equity is ranked better than
65.09% of 699 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs FRA:AOHA: 0.12

RUA Life Sciences Debt-to-Equity Historical Data

The historical data trend for RUA Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences Debt-to-Equity Chart

RUA Life Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.10

RUA Life Sciences Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.05	0.08	0.10	0.12

Competitive Comparison of RUA Life Sciences's Debt-to-Equity

For the Medical Devices subindustry, RUA Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RUA Life Sciences's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Debt-to-Equity falls into.

RUA Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

RUA Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.125	+	0.414)	/	5.308
	=	0.10

RUA Life Sciences's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.146	+	0.37)	/	4.33
	=	0.12

RUA Life Sciences (FRA:AOHA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

RUA Life Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

RUA Life Sciences (FRA:AOHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RUA:UK

Address

2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN

Website

https://www.rualifesciences.com

RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.

RUA Life Sciences (FRA:AOHA) Headlines

No Headlines